Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option.Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options.Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors. © 2014 Informa UK, Ltd.
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
Donato F.First
;Gay F.;Bringhen S.
;Troia R.;Palumbo A.Last
2014-01-01
Abstract
Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option.Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options.Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors. © 2014 Informa UK, Ltd.File | Dimensione | Formato | |
---|---|---|---|
[PUBLISHED Vsn.] Donato et al - 2014 - Monoclonal antibodies currently in Phase II and III trials.pdf
Accesso riservato
Descrizione: [PUBLISHED Vsn.] Donato et al - 2014 -
Tipo di file:
PDF EDITORIALE
Dimensione
551.93 kB
Formato
Adobe PDF
|
551.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.